Robert Timmerman, MD

Treating multiple oligometastatic lesions typically requires creating separate SBRT plans, resulting in longer treatment time and an increase in planning complexity. In this work we evaluate biology-guided multi-target treatment (MTT) approach for a PET-linea...

Rectal spacers are widely used in prostate stereotactic ablative radiotherapy (SAbR) to reduce rectal dose; however, their value as a practical, planning-oriented QA tool remains underdefined. Using real-world clinical trial data, this study evaluates whether...

Clinical trials require the extraction of specific metrics from DICOM plan datasets for protocol-driven data analysis. Because these metrics vary widely across trials, it has been difficult to develop an automated system capable of supporting diverse study re...

To address fragmentation and variability in longitudinal brain lesion assessment, we developed Brain-Dynamics, a vendor-neutral platform integrating auto‑segmentation, multimodal co‑registration, lesion labeling/tracking, and quantitative analytics for resear...

Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy (PULSAR) delivers high-dose radiation pulses separated by intervals of several weeks, enabling tumor response–guided adaptation, reduced toxicity, and potential synergy with immunotherapy. How...

Predicting tumor radiosensitivity remains a major challenge in precision radiotherapy due to incomplete concordance between transcriptomic alterations and functional protein expression. This study aims to develop an integrated transcriptomic–proteomic framewo...

FLASH radiotherapy delivers curative dose to tumor at ultra-high dose rates (UHDR,>40Gy/s) while mitigating normal tissue toxicity. However, data on late-responding tissues are limited, halting its safe clinical translation. Owing to its steep dose–response a...